+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID01624805

Phase II Study of Combination Therapy Including Horse Anti-Thymocyte Globulin, Methylprednisolone, Cyclosporine, and GCSF for Adults With Aplastic Anemia or Low to Intermediate-Risk Myelodysplastic Syndrome

Led by M.D. Anderson Cancer Center · Updated on 2026-06-22

140

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination treatment involving methylprednisolone, horse anti-thymocyte globulin hATG, cyclosporine, filgrastim, andor pegfilgrastim or its biosimilar in patients with aplastic anemia or low to intermediate-risk myelodysplastic syndrome. This phase II trial aims to determine how well this treatment works to improve blood counts by targeting immune cells believed to cause these diseases, as well as to assess its safety and overall patient survival. During the treatment phase, patients receive methylprednisolone intravenously for the first 4 days and then either intravenously or orally with a tapering dose up to day 30. Horse anti-thymocyte globulin is given intravenously over 8 hours daily for 4 days. Cyclosporine is taken orally twice daily for 180 days. Patients also receive pegfilgrastim or its biosimilar as a single subcutaneous dose on day 5 andor filgrastim starting on day 5 and continuing until white blood cell counts recover. Treatment continues for up to 6 months unless the disease worsens or side effects become unacceptable. Participants are closely monitored during the study with follow-up visits every 6 to 12 months after treatment ends. Researchers assess blood response, the time to response, duration of response, overall survival, and any side effects experienced. The primary outcome measured is the achievement of blood count response, with safety and survival tracked for up to 6 years, ensuring long-term monitoring of participants health and treatment effects.

CONDITIONS

Brief Title

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Research Team

T

Tapan Kadia, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here